Evidence map›Paper›PMID 40410560›Full record

ArticleInternational urology and nephrology2025

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension among PD patients.

Yanhong Guo, Silu Zhao, Xuewen Zhang, Rong Gou, Liuwei Wang, Yulin Wang, Zihan Zhai, Lu Yu, Lin Tang

Abstract read
PubMed Publisher
In one paragraph

Article in International urology and nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Yanhong Guo *Department of Nephropathy, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
Silu Zhao *Department of Nephropathy, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
Xuewen Zhang *Department of Nephropathy, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
Rong GouDepartment of Nephropathy, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
Liuwei WangDepartment of Nephropathy, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
Yulin WangDepartment of Nephropathy, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
Zihan ZhaiDepartment of Nephropathy, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
Lu YuDepartment of Nephropathy, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China.
Lin TangDepartment of Nephropathy, The First Affiliated Hospital of Zhengzhou University, No. 1 East Jianshe Road, Zhengzhou, 450052, Henan, China. tanglin@zzu.edu.cn.

Funding

National Natural Science Foundation of China,China 82200839National Natural Science Foundation of China,China 82370727
6 · The paper itself

Abstract

purposePulmonary hypertension is an independent risk factor for all-cause mortality and cardiovascular events in peritoneal dialysis (PD) patients with heart failure with preserved ejection fraction (HFpEF). However, there is still no effective treatment. The aim of this study is to evaluate the efficacy and safety of sacubitril/valsartan in PD patients with HFpEF and pulmonary hypertension. PATIENTS AND

methods145 PD patients with HFpEF and pulmonary hypertension receiving sacubitril/valsartan were recruited in this study. 38 PD patients with HFpEF and pulmonary hypertension treated with angiotensin receptor blocker (ARB) were enrolled as the control group. The follow-up time was 3 months. We evaluate efficacy and safety of sacubitril/valsartan through biochemical parameters, and echocardiographic indicators, and adverse reactions.

resultsAt the end of follow-up, the pulmonary artery pressure was significantly lower [33.00 (23.00, 45.50) vs 48.00 (40.00, 54.00) mmHg, P < 0.001] after the treatment of sacubitril/valsartan. The percentage change of pulmonary artery pressure after the treatment of sacubitril/valsartan was significantly higher than that of ARB [-30.00 (-48.78, -8.23) vs -8.57 (-12.80, -0.85) %, P < 0.001]. As the biomarkers of heart failure, the levels N-terminal B-type natriuretic peptide precursor and cardiac troponin I were remarkably reduced after the treatment with sacubitril/valsartan. Sacubitril/valsartan can also attenuate left-ventricular remodeling among PD patients. While, ARB does not show significant advantages compared to sacubitril/valsartan.

conclusionOur study suggested that sacubitril/valsartan treatment might be an effective treatment for PD patients with HFpEF and pulmonary hypertension.

Indexed as

AminobutyratesAngiotensin Receptor AntagonistsArterial PressureHeart FailureHypertension, PulmonaryTetrazolesValsartanAgedBiphenyl CompoundsDrug CombinationsFemaleHumansMaleMiddle AgedStroke VolumeAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug Combinationssacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartanAngiotensin receptor blockerPeritoneal dialysisPulmonary hypertensionSacubitril/valsartan

Identifiers

PMID40410560

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.